JP2016506935A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016506935A5 JP2016506935A5 JP2015555508A JP2015555508A JP2016506935A5 JP 2016506935 A5 JP2016506935 A5 JP 2016506935A5 JP 2015555508 A JP2015555508 A JP 2015555508A JP 2015555508 A JP2015555508 A JP 2015555508A JP 2016506935 A5 JP2016506935 A5 JP 2016506935A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- salt according
- salt
- alkyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 32
- 150000003839 salts Chemical class 0.000 claims 28
- 241001465754 Metazoa Species 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 208000019693 Lung disease Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 208000028394 ureteral disease Diseases 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 206010020853 Hypertonic bladder Diseases 0.000 claims 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims 1
- 102100040479 P2X purinoceptor 2 Human genes 0.000 claims 1
- 101710189968 P2X purinoceptor 2 Proteins 0.000 claims 1
- 102100040460 P2X purinoceptor 3 Human genes 0.000 claims 1
- 101710189970 P2X purinoceptor 3 Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 208000020629 overactive bladder Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361759123P | 2013-01-31 | 2013-01-31 | |
| US61/759,123 | 2013-01-31 | ||
| PCT/CA2014/050062 WO2014117274A1 (en) | 2013-01-31 | 2014-01-31 | Imidazopyridine compounds and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016506935A JP2016506935A (ja) | 2016-03-07 |
| JP2016506935A5 true JP2016506935A5 (enExample) | 2017-11-30 |
| JP6373280B2 JP6373280B2 (ja) | 2018-08-15 |
Family
ID=51261357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015555508A Active JP6373280B2 (ja) | 2013-01-31 | 2014-01-31 | イミダゾピリジン化合物及びその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (9) | US9598409B2 (enExample) |
| EP (3) | EP3381917B1 (enExample) |
| JP (1) | JP6373280B2 (enExample) |
| KR (1) | KR102120513B1 (enExample) |
| CN (2) | CN105246888B (enExample) |
| AU (1) | AU2014211962B2 (enExample) |
| BR (1) | BR112015018317B1 (enExample) |
| CA (1) | CA2898665C (enExample) |
| DK (2) | DK3381917T3 (enExample) |
| ES (2) | ES2895225T3 (enExample) |
| MX (1) | MX372934B (enExample) |
| NO (1) | NO2910833T3 (enExample) |
| PL (2) | PL3381917T3 (enExample) |
| PT (2) | PT2951177T (enExample) |
| RU (1) | RU2656593C2 (enExample) |
| TR (1) | TR201807602T4 (enExample) |
| WO (1) | WO2014117274A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2898665C (en) | 2013-01-31 | 2021-02-16 | Neomed Institute | Imidazopyridine compounds and their use as p2x purinoreceptor modulators |
| JP6544665B2 (ja) | 2014-12-09 | 2019-07-17 | バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | １，３−チアゾール−２−イル置換ベンズアミド |
| US9907795B2 (en) * | 2016-01-08 | 2018-03-06 | Nerre Therapeutics Limited | Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents |
| US10174039B2 (en) * | 2016-09-30 | 2019-01-08 | Asana Biosciences, Llc | P2X3 and/or P2X2/3 compounds and methods |
| EP3339307A1 (en) * | 2016-12-20 | 2018-06-27 | Laboratorios del Dr. Esteve, S.A. | Nitrogen containing bicyclic derivatives for treating pain and pain related conditions |
| US10111883B1 (en) | 2017-09-18 | 2018-10-30 | Bellus Health Cough Inc. | Selective P2X3 modulators |
| PL3862000T3 (pl) | 2018-10-05 | 2024-03-18 | Shionogi & Co., Ltd | Lek na przewlekły kaszel |
| US20210346391A1 (en) * | 2018-10-10 | 2021-11-11 | Bellus Health Cough Inc. | Treatment of pruritus with p2x3 modulators |
| PL3880678T3 (pl) * | 2018-11-13 | 2025-08-04 | Glaxosmithkline Intellectual Property (No.3) Limited | Postacie krystaliczne modulatora p2x3: (s)-2-((2-(2,6-difluoro-4- (metylokarbamoilo)fenylo)-7-metyloimidazo[1,2-a]pirydyn-3-ylo)metylo)morfolino-4-karboksylanu metylu |
| AU2019416589B2 (en) * | 2018-12-29 | 2023-04-06 | Wuhan Ll Science And Technology Development Co., Ltd. | Heterocyclic compound intermediate, preparation method therefor and application thereof |
| WO2020174283A1 (en) * | 2019-02-25 | 2020-09-03 | Bellus Health Cough Inc. | Treatment with p2x3 modulators |
| CN112409331B (zh) * | 2019-08-21 | 2024-02-20 | 上海翰森生物医药科技有限公司 | 杂环类衍生物抑制剂、其制备方法和应用 |
| JP7693691B2 (ja) * | 2020-02-14 | 2025-06-17 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー３）、リミテッド | Ｐ２ｘ３アンタゴニストの製造 |
| CN115413279A (zh) * | 2020-02-14 | 2022-11-29 | 贝卢斯医疗咳嗽病公司 | P2x3调节剂 |
| CN113549068B (zh) * | 2020-04-24 | 2022-12-02 | 上海拓界生物医药科技有限公司 | 一类新型咪唑并吡啶化合物、其制备方法及其在医药上的应用 |
| CN113754654A (zh) * | 2020-06-05 | 2021-12-07 | 武汉人福创新药物研发中心有限公司 | 咪唑并吡啶类化合物及其用途 |
| CN114085220B (zh) * | 2020-06-22 | 2023-06-16 | 上海海雁医药科技有限公司 | 取代的吗啉-4-羧酸酯衍生物、其组合物及医药上的用途 |
| EP4169921A4 (en) * | 2020-06-29 | 2024-06-19 | Wuhan LL Science and Technology Development Co., Ltd. | Crystalline form of heterocyclic compound, preparation method therefor and application thereof |
| CN113912601B (zh) * | 2020-07-10 | 2023-06-06 | 上海拓界生物医药科技有限公司 | 一类新的咪唑并[1,2-a]吡啶类衍生物、其制备方法及医药用途 |
| JP2023536986A (ja) * | 2020-08-13 | 2023-08-30 | 上海拓界生物医薬科技有限公司 | ベンズイミダゾール誘導体、その調製方法及び医薬用途 |
| CN112485351A (zh) * | 2020-11-18 | 2021-03-12 | 天津华津制药有限公司 | 一种右佐匹克隆光学异构体的检测方法 |
| TW202227458A (zh) * | 2020-12-04 | 2022-07-16 | 大陸商上海拓界生物醫藥科技有限公司 | 含有稠合三環的化合物及其醫藥用途 |
| WO2022156783A1 (zh) * | 2021-01-22 | 2022-07-28 | 武汉人福创新药物研发中心有限公司 | 咪唑并吡啶类化合物的制备方法及其中间体 |
| CN114805237B (zh) * | 2021-01-22 | 2026-04-21 | 武汉人福创新药物研发中心有限公司 | 杂环类化合物的制备方法及其中间体 |
| CN115463133B (zh) * | 2021-06-10 | 2024-03-01 | 武汉朗来科技发展有限公司 | 一种药物组合物、制剂及其制备方法和应用 |
| CN117460720B (zh) * | 2021-06-24 | 2026-02-24 | 武汉朗来科技发展有限公司 | 一种杂环烷基类化合物的制备方法、其中间体及其应用 |
| US20240351992A1 (en) * | 2021-08-17 | 2024-10-24 | Glaxosmithkline Intellectual Property (No.3) Limited | Preparation of p2x3 antagonist |
| WO2023020156A1 (zh) * | 2021-08-20 | 2023-02-23 | 苏州璞正医药有限公司 | 一种咪唑并吡啶衍生物的p2x3受体选择性调节剂及其药物用途 |
| WO2024194352A1 (en) | 2023-03-23 | 2024-09-26 | Glaxosmithkline Intellectual Property (No.3) Limited | Deuterated p2x3 modulators |
| CN119490467A (zh) * | 2023-08-17 | 2025-02-21 | 武汉朗来科技发展有限公司 | 一种含二溴乙烯基的杂环烷化合物及其制备方法和应用 |
| WO2025125445A1 (en) | 2023-12-12 | 2025-06-19 | Glaxosmithkline Intellectual Property (No.3) Limited | Process of manufacture of p2x3 antagonists including camlipixant |
| WO2025191081A1 (en) | 2024-03-15 | 2025-09-18 | Glaxosmithkline Intellectual Property (No.3) Limited | Crystalline form of camlipixant |
| WO2025210540A1 (en) | 2024-04-02 | 2025-10-09 | Assia Chemical Industries Ltd. | Solid state forms of camlipixant and process for preparation thereof |
| WO2026022326A1 (en) | 2024-07-25 | 2026-01-29 | Glaxosmithkline Intellectual Property (No.3) Limited | P2x3 antagonist formulation |
| WO2026032924A1 (en) | 2024-08-06 | 2026-02-12 | Glaxosmithkline Intellectual Property (No.3) Limited | Camlipixant in combination with cyp3a4 and/or cyp2c8 inducers for use in the treatment of chronic cough |
| WO2026078027A1 (en) | 2024-10-10 | 2026-04-16 | Glaxosmithkline Intellectual Property (No.3) Limited | Dosage regimens for camlipixant in treating chronic cough |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9119920D0 (en) | 1991-09-18 | 1991-10-30 | Glaxo Group Ltd | Chemical compounds |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| WO1997030035A1 (en) | 1996-02-13 | 1997-08-21 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| ES2169355T3 (es) | 1996-03-05 | 2002-07-01 | Astrazeneca Ab | Derivados de 4-anilinoquinazolina. |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| BRPI0017548B8 (pt) | 1999-02-10 | 2023-05-02 | Astrazeneca Ab | Composto |
| IL152682A0 (en) | 2000-05-31 | 2003-06-24 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| BR0112224A (pt) | 2000-07-07 | 2003-06-10 | Angiogene Pharm Ltd | Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto |
| HUP0301742A3 (en) | 2000-07-07 | 2005-08-29 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use |
| SE0102808D0 (sv) * | 2001-08-22 | 2001-08-22 | Astrazeneca Ab | New compounds |
| MX2007003105A (es) | 2004-09-24 | 2007-06-07 | Aztrazeneca Ab | Derivados de bencimidazol, composiciones que los contienen, sus preparaciones y sus usos i. |
| DE102006028862A1 (de) | 2006-06-23 | 2007-12-27 | Merck Patent Gmbh | 3-Amino-imidazo[1,2-a]pyridinderivate |
| ES2604542T3 (es) * | 2006-06-29 | 2017-03-07 | F. Hoffmann-La Roche Ag | Arilamidas con sustitución tetrazol |
| US20090099195A1 (en) | 2007-05-08 | 2009-04-16 | Astrazeneca Ab | Therapeutic Compounds 570 |
| AU2010229142A1 (en) * | 2009-03-23 | 2011-10-13 | Merck Sharp & Dohme Corp. | P2X3, receptor antagonists for treatment of pain |
| TW201121957A (en) | 2009-11-18 | 2011-07-01 | Astrazeneca Ab | Benzoimidazole compounds and uses thereof |
| CA2898665C (en) | 2013-01-31 | 2021-02-16 | Neomed Institute | Imidazopyridine compounds and their use as p2x purinoreceptor modulators |
-
2014
- 2014-01-31 CA CA2898665A patent/CA2898665C/en active Active
- 2014-01-31 DK DK18158586.0T patent/DK3381917T3/da active
- 2014-01-31 WO PCT/CA2014/050062 patent/WO2014117274A1/en not_active Ceased
- 2014-01-31 EP EP18158586.0A patent/EP3381917B1/en active Active
- 2014-01-31 DK DK14745722.0T patent/DK2951177T3/en active
- 2014-01-31 US US14/764,404 patent/US9598409B2/en active Active
- 2014-01-31 CN CN201480007024.8A patent/CN105246888B/zh active Active
- 2014-01-31 CN CN201710680673.XA patent/CN107485612B/zh active Active
- 2014-01-31 BR BR112015018317-4A patent/BR112015018317B1/pt active IP Right Grant
- 2014-01-31 TR TR2018/07602T patent/TR201807602T4/tr unknown
- 2014-01-31 AU AU2014211962A patent/AU2014211962B2/en active Active
- 2014-01-31 PT PT147457220T patent/PT2951177T/pt unknown
- 2014-01-31 PT PT18158586T patent/PT3381917T/pt unknown
- 2014-01-31 JP JP2015555508A patent/JP6373280B2/ja active Active
- 2014-01-31 EP EP14745722.0A patent/EP2951177B1/en active Active
- 2014-01-31 ES ES18158586T patent/ES2895225T3/es active Active
- 2014-01-31 RU RU2015133450A patent/RU2656593C2/ru active
- 2014-01-31 ES ES14745722.0T patent/ES2674087T3/es active Active
- 2014-01-31 KR KR1020157023171A patent/KR102120513B1/ko active Active
- 2014-01-31 PL PL18158586T patent/PL3381917T3/pl unknown
- 2014-01-31 PL PL14745722T patent/PL2951177T3/pl unknown
- 2014-01-31 MX MX2015009950A patent/MX372934B/es active IP Right Grant
- 2014-01-31 EP EP21195015.9A patent/EP3998267A1/en active Pending
-
2015
- 2015-01-30 NO NO15153188A patent/NO2910833T3/no unknown
-
2017
- 2017-02-02 US US15/423,428 patent/US9814725B2/en active Active
- 2017-09-26 US US15/716,410 patent/US9937185B2/en active Active
-
2018
- 2018-02-27 US US15/906,230 patent/US20190030040A1/en not_active Abandoned
-
2019
- 2019-04-04 US US16/375,773 patent/US20190231789A1/en not_active Abandoned
-
2020
- 2020-01-07 US US16/736,599 patent/US20200138826A1/en not_active Abandoned
- 2020-08-27 US US17/005,238 patent/US20200390779A1/en not_active Abandoned
-
2021
- 2021-04-08 US US17/225,753 patent/US20210228588A1/en not_active Abandoned
- 2021-11-10 US US17/523,767 patent/US20220062290A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015133450A (ru) | Соединения имидазопиридина и их применение | |
| CY1118813T1 (el) | Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων | |
| MX2016010266A (es) | Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso. | |
| EA201491329A1 (ru) | 4,4-дизамещенные 1,4-дигидропиримидины и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| EA201491672A1 (ru) | Гетероциклильные соединения как ингибиторы mek | |
| BR112015021983A8 (pt) | compostos heterocíclicos, composições e usos dos mesmos | |
| EA201592200A1 (ru) | Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b | |
| EA201200318A1 (ru) | Гетероциклические оксимы | |
| RU2018106453A (ru) | Соединения | |
| JP2015537020A5 (enExample) | ||
| EA201401082A1 (ru) | Фармацевтические препараты, содержащие антагонисты ccr3 | |
| JP2014506907A5 (enExample) | ||
| EA201301240A1 (ru) | Полиморфная форма бензоата линаглиптина | |
| JP2014507455A5 (enExample) | ||
| EA201201658A1 (ru) | Производные пиперидина и их применение для лечения метаболических нарушений | |
| WO2013061004A8 (fr) | Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines | |
| EA201590562A1 (ru) | Бензамиды | |
| EA201691918A1 (ru) | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения | |
| WO2013028818A8 (en) | Pyrimido- pyridazinone compounds and use thereof | |
| CA2894891A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
| EA033054B1 (ru) | Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения | |
| RU2015135824A (ru) | Бициклические соединения пиримидона в качестве ингибиторов lp-pla2 | |
| WO2016057658A8 (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
| RU2015135806A (ru) | Соединения |